



## Millendo Therapeutics to Participate in May Investor Conferences

May 2, 2019

ANN ARBOR, Mich.--(BUSINESS WIRE)--May 2, 2019-- [Millendo Therapeutics, Inc.](http://www.millendo.com) (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that management will present company overviews at the following healthcare investor conferences:

- **2019 SunTrust Robison Humphrey 5th Annual Life Sciences Summit** on Tuesday, May 7, 2019 in New York, where one-on-one investor meetings will be held.
- **2019 RBC Capital Markets Global Healthcare Conference** on Wednesday, May 22, 2019 at 10:00 a.m. EST in New York. A live webcast of the presentation will be available on the Investors & Media section of Millendo's website at <http://investors.millendo.com>. A replay of the webcast will be archived on Millendo's website for 30 days following the presentation.

### About Millendo Therapeutics, Inc.

Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing's syndrome. For more information, please visit [www.millendo.com](http://www.millendo.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190502005167/en/>

Source: Millendo Therapeutics, Inc.

### Millendo Investor Contact:

Stephanie Ascher  
Stern Investor Relations  
212-362-1200  
[stephanie.ascher@sternir.com](mailto:stephanie.ascher@sternir.com)

### Millendo Media Contact:

Betsy Yates  
MacDougall  
781-235-3094  
[byates@macbiocom.com](mailto:byates@macbiocom.com)